Duodenal somatostatinoma presenting as obstructive jaundice with the coexistence of a gastrointestinal stromal tumour in neurofibromatosis type 1: a case with review of the literature

BMJ Case Rep. 2019 Jan 10;12(1):bcr-2018-226702. doi: 10.1136/bcr-2018-226702.

Abstract

Somatostatinomas are rare neuroendocrine tumours, mostly located in the pancreas or duodenum, with an estimated incidence of 1 in 40 million. Duodenal somatostatinomas (DSs) are usually found in association with neurofibromatosis type 1 (NF1), tuberous sclerosis and Von Hippel-Lindau syndrome. Gastrointestinal stromal tumours (GIST) have also been described in NF1, but the association with somatostatinoma is very uncommon. We report the case of a patient with NF1 who presented with obstructive jaundice due to multiple firm nodules around the ampulla of Vater. A pancreaticoduodenectomy was performed and revealed a 1 cm duodenal/ampullary mass which stained positive for somatostatin, together with a GIST also found on the duodenal wall. Despite its rarity, ampullary somatostatinomas should be considered in the differential diagnosis of biliary tract dilation in patients with NF1.

Keywords: endocrine cancer; neuro genetics; neuroendocrinology.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Aftercare
  • Diagnosis, Differential
  • Duodenal Neoplasms / pathology
  • Duodenal Neoplasms / surgery
  • Female
  • Gastrointestinal Stromal Tumors / complications*
  • Gastrointestinal Stromal Tumors / pathology
  • Gastrointestinal Stromal Tumors / surgery
  • Humans
  • Jaundice, Obstructive / diagnosis*
  • Jaundice, Obstructive / etiology
  • Jaundice, Obstructive / surgery
  • Neuroendocrine Tumors / epidemiology
  • Neurofibromatosis 1 / complications*
  • Neurofibromatosis 1 / diagnosis
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / surgery
  • Pancreaticoduodenectomy / methods
  • Somatostatin / metabolism
  • Somatostatinoma / complications
  • Somatostatinoma / pathology*
  • Somatostatinoma / surgery
  • Treatment Outcome

Substances

  • Somatostatin